导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.60% | 3279/4773 |
| 近一周 | -2.18% | 1411/5462 |
| 近一月 | -4.52% | 2535/5421 |
| 近一季 | -9.07% | 3089/5209 |
| 近半年 | -5.38% | 2841/4920 |
| 近一年 | -2.92% | 3033/4366 |
| 近两年 | 37.49% | 1996/2954 |
| 近三年 | 24.51% | 1301/2253 |
| 成立以来 | 77.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.30% 2752/4961 |
9.67% 2470/5312 |
- - |
- - |
| 2025 | 21.02% 2062/4813 |
2.37% 1392/3635 |
2.40% 1588/4076 |
15.15% 2839/4524 |
0.25% 2101/4813 |
| 2024 | 17.23% 711/3463 |
2.88% 682/2808 |
2.42% 352/3014 |
14.33% 2004/3129 |
-2.68% 2158/3463 |
| 2023 | -6.93% 883/2656 |
7.33% 583/2280 |
-3.65% 856/2385 |
-2.79% 751/2515 |
-7.42% 2141/2655 |
| 2022 | -20.97% 1005/2207 |
-10.84% 433/1919 |
4.00% 1069/2016 |
-12.21% 669/2113 |
-2.92% 1823/2208 |
| 2021 | 0.75% 706/1822 |
-0.80% 394/1255 |
10.94% 420/1330 |
-6.83% 997/1466 |
-1.73% 1385/1822 |
| 2020 | 46.35% 211/1250 |
-2.74% 273/1028 |
15.01% 522/1067 |
14.30% 285/1164 |
14.47% 272/1184 |
| 2019 | - - |
- - |
- - |
2.48% 298/850 |
9.15% 250/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 长信沪深300指数增强C VS. 长安沪深300非周期A(740101) |